You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

MinervaX begins critical GBS vaccine trial

MinervaX – a biotechnology concentrating on a group B streptococcus (GBS) vaccine – has announced the first phase 1 clinical study among older adults. The research will unfold at the CEVAC (Centre for Vaccinology) in Belgium.